Kiromic Biopharma, Inc. Retained Earnings
Kiromic Biopharma, Inc. had Retained Earnings of -$149.79 million as of 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-02-14
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$149.79M.
- 2024-09-30: Retained Earnings (Accumulated Deficit) -$143.30M.
- 2024-06-30: Retained Earnings (Accumulated Deficit) -$135.87M.
- 2024-03-31: Retained Earnings (Accumulated Deficit) -$129.04M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2024-12-31 | -$149.79M 10-K · filed 2025-02-14 | |
| 2024-09-30 | -$143.30M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | -$135.87M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | -$129.04M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | -$122.90M 10-K · filed 2025-02-14 | -$122.90M 10-K · filed 2024-03-19 |
| 2023-09-30 | -$118.21M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$114.01M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$107.25M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$101.95M 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$94.88M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$83.02M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$74.58M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$67.22M 10-K · filed 2023-04-17 | |
| 2021-09-30 | -$56.58M 10-Q · filed 2022-03-11 | |
| 2021-06-30 | -$50.46M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | -$45.48M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | -$41.63M 10-K · filed 2022-04-08 | |
| 2020-09-30 | -$38.06M 10-Q · filed 2020-11-30 | |
| 2019-12-31 | -$22.43M 10-K · filed 2021-03-31 |